Last reviewed · How we verify
Folotyn and Leucovorin
Folotyn and Leucovorin is a Antineoplastic agent Small molecule drug developed by Acrotech Biopharma Inc.. It is currently in Phase 2 development for Relapsed or refractory peripheral T-cell lymphoma, Relapsed or refractory cutaneous T-cell lymphoma. Also known as: Pralatrexate (Folotyn).
Folotyn is a pegylated form of calicheamicin, a potent antitumor antibiotic that binds to DNA and inhibits RNA synthesis, while Leucovorin is a folate analog that inhibits dihydrofolate reductase, thereby increasing the effectiveness of folate-dependent drugs.
Folotyn is a pegylated form of calicheamicin, a potent antitumor antibiotic that binds to DNA and inhibits RNA synthesis, while Leucovorin is a folate analog that inhibits dihydrofolate reductase, thereby increasing the effectiveness of folate-dependent drugs. Used for Relapsed or refractory peripheral T-cell lymphoma, Relapsed or refractory cutaneous T-cell lymphoma.
At a glance
| Generic name | Folotyn and Leucovorin |
|---|---|
| Also known as | Pralatrexate (Folotyn) |
| Sponsor | Acrotech Biopharma Inc. |
| Drug class | Antineoplastic agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Folotyn works by binding to DNA and inhibiting RNA synthesis, which ultimately leads to cell death. Leucovorin, on the other hand, is used to enhance the effectiveness of folate-dependent drugs like methotrexate, which is often used in combination with Folotyn in the treatment of certain cancers.
Approved indications
- Relapsed or refractory peripheral T-cell lymphoma
- Relapsed or refractory cutaneous T-cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
Key clinical trials
- Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma (PHASE1, PHASE2)
- Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn (PHASE1)
- Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® (PHASE1)
- Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Folotyn and Leucovorin CI brief — competitive landscape report
- Folotyn and Leucovorin updates RSS · CI watch RSS
- Acrotech Biopharma Inc. portfolio CI
Frequently asked questions about Folotyn and Leucovorin
What is Folotyn and Leucovorin?
How does Folotyn and Leucovorin work?
What is Folotyn and Leucovorin used for?
Who makes Folotyn and Leucovorin?
Is Folotyn and Leucovorin also known as anything else?
What drug class is Folotyn and Leucovorin in?
What development phase is Folotyn and Leucovorin in?
What are the side effects of Folotyn and Leucovorin?
Related
- Drug class: All Antineoplastic agent drugs
- Manufacturer: Acrotech Biopharma Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Relapsed or refractory peripheral T-cell lymphoma
- Indication: Drugs for Relapsed or refractory cutaneous T-cell lymphoma
- Also known as: Pralatrexate (Folotyn)
- Compare: Folotyn and Leucovorin vs similar drugs
- Pricing: Folotyn and Leucovorin cost, discount & access